デジタルセラピューティクスの市場規模、シェア、動向分析レポート：用途別、最終用途別、地域別、セグメント予測、2024年～2030年

デジタルセラピューティクス市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のデジタルセラピューティクス市場規模は、2024年から2030年にかけて27.2％のCAGRを示し、2030年には325億2,000万米ドルに達する見込みです。

市場成長を拡大する主な要因は、スマートフォンの普及です。ヘルスケアプロバイダーや患者にとってデジタルヘルス技術が手ごろな価格で入手可能であること、統合ヘルスケアシステムに対する需要の高まり、患者に焦点を当てたケアが市場の成長を促進する主な要因です。さらに、世界化の進展や、タバコの使用率の上昇、栄養不足、運動不足、アルコール消費量の増加といった生活習慣の変化が、慢性疾患発症の可能性を高めています。

市場の拡大は、デジタルセラピューティクスの採用増加や、FDAなどの主要規制機関による支援策に大きく影響されています。例えば、米国FDAは2020年4月、精神疾患を患う人々に対するデジタルセラピューティクス機器の普及を強化するためのガイドラインを提示しました。さらに、ケピオスのデータによると、世界のインターネット・ユーザーの年間成長率は7.6%で、毎日約90万人の新規インターネット・ユーザーが利用していることになります。先進国も発展途上国もスマートフォンやインターネットの利用レベルは高いが、アフリカや南アジアなどの地域は経済的な制約があるため、追いつく必要があります。

慢性疾患の有病率の増加も市場の成長を後押ししています。CDCのNational Center for Chronic Disease Prevention and Health Promotionによると、アメリカの成人の10人に6人が慢性疾患を患っており、成人の10人に4人は2つ以上の慢性疾患を抱えています。例えば、2022年2月、Teladoc Health, Inc.は、ヘルスケアの成果を改善するための慢性疾患管理ソリューション、Chronic Care Completeを発表しました。心血管疾患、がん、糖尿病、慢性腎臓病、慢性肺疾患、アルツハイマー病は、国内における死亡と身体障害の主な原因として特定されています。

デジタルセラピューティクスは、主に業界の主要企業によるカスタマイズされた治療計画や戦略的取り組みにより、様々な健康状態の治療に不可欠な選択肢となっています。こうした行動には、合併・買収、規制当局の承認の取得、新製品の導入、パートナーシップの確立などが含まれます。さらに、心血管疾患、糖尿病、不安などの慢性疾患の割合が増加していることが、市場の重要なプレーヤーが治療のためのデジタル・ソリューションに投資する原動力となっています。さまざまな企業が不安管理に特化したデジタルセラピューティクス製品の開発を進めており、これらの製品の多くは研究開発のさまざまな段階にあります。これは市場成長にとって大きな機会となります。例えば、2023年8月、ウェルドックは、糖尿病管理用デジタルヘルス・ソリューションBlueStarの10回目のFDA 510（k）クリアランスを取得したことを明らかにしました。この認可により、BlueStarは接続されたインスリン投与情報をボーラスインスリン投与のためのカスタマイズされた推奨に組み込むことができます。

デジタルセラピューティクス市場レポートハイライト

• 用途別では、糖尿病が2023年に29.36%の市場シェアを占め、これは同分野の市場参入企業による急速な技術進歩によるものです。また、同セグメントは予測期間中に最も急速な成長が見込まれます。
• 患者セグメントは、慢性疾患に苦しむ患者数の増加により、2023年に34.08%の最大市場シェアを占めました。デジタルセラピューティクスは、特に地方や遠隔地の人々の治療へのアクセスを改善するのにも役立ちます。
• 北米はデジタルセラピューティクスに対する需要が高いため、2023年の世界市場を独占しました。これらの地域マーケットプレースは、予測期間中、ヘルスケア意識の高まりとデジタルヘルス製品の利用増加により、同様の動向を示すと予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 デジタルセラピューティクス市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• デジタルセラピューティクス市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 デジタルセラピューティクス市場：用途別推定・動向分析

• 用途別市場シェア、2023年および2030年
• セグメントダッシュボード
• 用途別世界デジタルセラピューティクス市場の展望
• 糖尿病
  • 市場推計・予測、2018年～2030年
• 肥満
  • 市場推計・予測、2018年～2030年
• 心血管疾患（CVD）
  • 市場推計・予測、2018年～2030年
• 呼吸器疾患
  • 市場推計・予測、2018年～2030年
• 禁煙
  • 市場推計・予測、2018年～2030年
• 中枢神経系（CNS）疾患
  • 市場推計・予測、2018年～2030年
• その他
  • 市場推計・予測、2018年～2030年

第5章 デジタルセラピューティクス市場：最終用途別推定・動向分析

• 最終用途別市場シェア、2023年および2030年
• セグメントダッシュボード
• 最終用途別世界デジタルセラピューティクス市場展望
• 患者
• プロバイダー
• 支払者
• 雇用主
• その他

第6章 デジタルセラピューティクス市場：地域推定・動向分析、用途別、最終用途別

• 地域別市場シェア分析、2023年および2030年
• 地域市場ダッシュボード
• 世界地域市場スナップショット
• 市場規模、予測動向分析、2018年から2030年：
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• 企業プロファイル
  • OMADA HEALTH, INC.
  • Welldoc, Inc.
  • 2Morrow, Inc
  • Livongo Health, Inc.（Teladoc Health, Inc.）
  • Propeller Health（ResMed）
  • Fitbit LLC
  • Mango Health
  • CANARY HEALTH
  • Noom, Inc.
  • Pear Therapeutics, Inc.
  • Akili Interactive Labs, Inc.
  • HYGIEIA
  • DarioHealth Corp.
  • BigHealth
  • GAIA AG
  • Limbix Health, Inc.

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviation
• Table 3 North America digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
• Table 4 North America digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 5 North America digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 6 U.S. macro dynamics
• Table 7 U.S. digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 8 U.S. digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 9 Canada macro dynamics
• Table 10 Canada digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 11 Canada digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 12 Mexico macro dynamics
• Table 13 Mexico digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 14 Mexico digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 15 Europe digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
• Table 16 Europe digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 17 Europe digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 18 UK macro dynamics
• Table 19 UK digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 20 UK digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 21 Germany macro dynamics
• Table 22 Germany digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 23 Germany digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 24 France macro dynamics
• Table 25 France digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 26 France digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 27 Italy macro dynamics
• Table 28 Italy digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 29 Italy digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 30 Spain macro dynamics
• Table 31 Spain digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 32 Spain digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 33 Denmark macro dynamics
• Table 34 Denmark digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 35 Denmark digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 36 Sweden macro dynamics
• Table 37 Sweden digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 38 Sweden digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 39 Norway macro dynamics
• Table 40 Norway digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 41 Norway digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 42 Asia Pacific digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 44 Asia Pacific digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 45 Asia Pacific digital therapeutics market estimates and forecasts, by therapeutic application, 2018 - 2030 (USD Million)
• Table 46 Japan macro dynamics
• Table 47 Japan digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 48 Japan digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 49 China macro dynamics
• Table 50 China digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 51 China digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 52 India macro dynamics
• Table 53 India digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 54 India digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 55 Australia Macro dynamics
• Table 56 Australia digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 57 Australia digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 58 Thailand macro dynamics
• Table 59 Thailand digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 60 Thailand digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 61 South Korea macro dynamics
• Table 62 South Korea digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 63 South Korea digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 64 Latin America digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
• Table 65 Latin America digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 66 Latin America digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 67 Brazil macro dynamics
• Table 68 Brazil digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 69 Brazil digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 70 Argentina macro dynamics
• Table 71 Argentina digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 72 Argentina digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 73 MEA digital therapeutics market estimates and forecasts, by country, 2018 - 2030 (USD Million)
• Table 74 MEA digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 75 MEA digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 76 South Africa macro dynamics
• Table 77 South Africa digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 78 South Africa digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 79 Saudi Arabia Macro dynamics
• Table 80 Saudi Arabia digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 81 Saudi Arabia digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 82 UAE Macro dynamics
• Table 83 UAE digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 84 UAE digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 85 Kuwait Macro dynamics
• Table 86 Kuwait digital therapeutics market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 87 Kuwait digital therapeutics market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
• Table 88 Key company heat map analysis/company position analysis

List of Figures

• Fig. 1 Market segmentation
• Fig. 2 Market research process
• Fig. 3 Estimation methodology
• Fig. 4 Data triangulation techniques
• Fig. 5 Primary research pattern
• Fig. 6 Market research approaches
• Fig. 7 Value-chain-based sizing & forecasting
• Fig. 8 QFD modeling for market share assessment
• Fig. 9 Market formulation & validation
• Fig. 10 Commodity flow analysis
• Fig. 11 Digital therapeutics market snapshot, 2023 (USD Million)
• Fig. 12 Segment snapshot
• Fig. 13 Competitive landscape snapshot
• Fig. 14 Parent market outlook
• Fig. 15 Ancillary market outlook
• Fig. 16 Digital Therapeutics market dynamics
• Fig. 17 Digital therapeutics market driver impact
• Fig. 18 Annual cost per person (USD) for key chronic conditions & by no. of co-morbidities
• Fig. 19 Top countries by smartphone users, 2021
• Fig. 20 Digital therapeutics market restraint impact
• Fig. 21 Market participation categorization
• Fig. 22 Market leaders and innovators
• Fig. 23 Company market position analysis
• Fig. 24 Major deals & strategic alliances analysis
• Fig. 25 Digital therapeutics market: Application movement analysis
• Fig. 26 Digital therapeutics Market: Application dashboard
• Fig. 27 Global diabetes market, 2018 - 2030 (USD Million)
• Fig. 28 Global obesity market, 2018 - 2030 (USD Million)
• Fig. 29 Global CVD market, 2018 - 2030 (USD Million)
• Fig. 30 Global respiratory diseases market, 2018 - 2030 (USD Million)
• Fig. 31 Global smoking cessation market, 2018 - 2030 (USD Million)
• Fig. 32 Global CNS diseases market, 2018 - 2030 (USD Million)
• Fig. 33 Global others market, 2018 - 2030 (USD Million)
• Fig. 34 Digital therapeutics market: End use movement analysis
• Fig. 35 Digital therapeutics market: End use dashboard
• Fig. 36 Global patients market, 2018 - 2030 (USD Million)
• Fig. 37 Global providers market, 2018 - 2030 (USD Million)
• Fig. 38 Global payers market, 2018 - 2030 (USD Million)
• Fig. 39 Global employers market, 2018 - 2030 (USD Million)
• Fig. 40 Global other end uses market, 2018 - 2030 (USD Million)
• Fig. 41 Regional marketplace: Key takeaways
• Fig. 42 North America: SWOT analysis
• Fig. 43 North America digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 44 U.S. digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 45 Canada digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 46 Mexico digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 47 Europe: SWOT analysis
• Fig. 48 Europe digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 49 UK digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 50 Germany digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 51 France digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 52 Italy digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 53 Spain digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 54 Sweden digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 55 Norway digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 56 Denmark digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 57 Asia Pacific: SWOT analysis
• Fig. 58 Asia Pacific Digital Therapeutics market, 2018 - 2030 (USD Million)
• Fig. 59 Japan digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 60 China digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 61 India digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 62 Australia digital therapeutics market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 South Korea digital therapeutics market estimates and forecasts, 2016 - 2030 (USD Million)
• Fig. 64 Thailand digital therapeutics market estimates and forecasts, 2016 - 2030 (USD Million)
• Fig. 65 Latin America: SWOT analysis
• Fig. 66 Latin America digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 67 Mexico digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 68 Brazil digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 69 Argentina digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 70 Middle East and Africa: SWOT analysis
• Fig. 71 Middle East and Africa digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 72 South Africa digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 73 Saudi Arabia digital therapeutics market, 2018 - 2030 (USD Million)
• Fig. 74 UAE digital therapeutics market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Kuwait digital therapeutics market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Heat map analysis
• Fig. 77 List of key emerging companies/technology disruptors/innovators

Digital Therapeutics Market Growth & Trends:

The global digital therapeutics market size is expected to reach USD 32.52 billion by 2030, exhibiting a CAGR of 27.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The primary driver for expanding the market growth is the increased use of smartphones. The affordability of digital health technologies for healthcare providers & patients, rising demand for integrated healthcare systems, and care focusing on the patient are key factors fueling the market's growth. Furthermore, the growing globalization and shifts in lifestyle habits, such as higher rates of tobacco use, inadequate nutrition, insufficient physical activity, and rising alcohol consumption, increase the likelihood of chronic disease development.

The market's expansion is significantly influenced by the increasing adoption of digital therapeutics and the supportive initiatives by leading regulatory agencies such as the FDA. For instance, the U.S. FDA provided guidelines in April 2020 to enhance the reach of digital therapeutic devices for people suffering from psychiatric disorders. Furthermore, according to Kepios data, there's a 7.6% annual growth rate in the global internet user base, translating to around 900,000 new internet users daily. While developed and developing nations boast high smartphone and internet usage levels, areas such as Africa and South Asia need to catch up due to their economic limitations.

Increasing prevalence of chronic diseases is also driving the growth of the market. As per the CDC's National Center for Chronic Disease Prevention and Health Promotion, 6 in 10 American adults suffer from a chronic disease, while 4 out of 10 adults have two or more chronic diseases. For instance, in February 2022, Teladoc Health, Inc. launched Chronic Care Complete, a chronic condition management solution to improve healthcare outcomes. Cardiovascular diseases, cancer, diabetes, chronic kidney disease, chronic lung disease, and Alzheimer's have been identified as the leading causes of death and disability in the country.

Digital therapeutics have become an essential option for treating various health conditions, mainly due to customized treatment plans and strategic initiatives by leading companies in the industry. These actions include mergers and acquisitions, clearing regulatory approvals, introducing new products, and establishing partnerships. Moreover, the growing rates of chronic diseases such as cardiovascular disease, diabetes, and anxiety have driven critical players in the market to invest in digital solutions for treatment. Various companies are in the process of developing digital therapeutic products aimed specifically at managing anxiety, with many of these products in different phases of research and development. This presents a significant opportunity for market growth. For instance, In August 2023, Welldoc revealed it had obtained its 10th FDA 510(k) clearance for the BlueStar digital health solution for diabetes management. This clearance allows BlueStar to incorporate connected insulin dosing information into its customized recommendations for bolus insulin dosing.

Digital Therapeutics Market Report Highlights:

• Based on application, diabetes held a market share of 29.36% in 2023, owing to rapid technological advancements by market players in the segment. The segment is also expected to witness the fastest growth over the forecast period
• The patients segment held the largest market share of 34.08% in 2023, owing to the growing number of patients suffering from chronic conditions. Digital therapeutics can also help improve access to care for people, especially those from rural and remote areas
• North America dominated the global market in 2023 owing to the high demand for digital therapeutics in the region. These regional marketplaces are expected to show similar trends throughout the forecast period due to rising healthcare awareness coupled with increased use of digital health products over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Application
  • 1.1.2. End Use
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application outlook
  • 2.2.2. End Use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Digital Therapeutics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Digital Therapeutics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Digital Therapeutics Market: Application Estimates & Trend Analysis

• 4.1. Application Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Digital Therapeutics Market by Application Outlook
• 4.4. Diabetes
  • 4.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.5. Obesity
  • 4.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.6. Cardiovascular Disease (CVD)
  • 4.6.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.7. Respiratory Diseases
  • 4.7.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.8. Smoking Cessation
  • 4.8.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.9. Central Nervous System (CNS) Disease
  • 4.9.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.10. Others
  • 4.10.1. Market estimates and forecast 2018 - 2030 (USD Million)

Chapter 5. Digital Therapeutics Market: End Use Estimates & Trend Analysis

• 5.1. End Use Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Digital Therapeutics Market by End Use Outlook
• 5.4. Patients
  • 5.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.5. Providers
  • 5.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.6. Payers
  • 5.6.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.7. Employers
  • 5.7.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Market estimates and forecast 2018 - 2030 (USD Million)

Chapter 6. Digital Therapeutics Market: Regional Estimates & Trend Analysis, By Application, By End Use

• 6.1. Regional Market Share Analysis, 2023 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.3. Mexico
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.6. Denmark
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/ reimbursement structure
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.8. Norway
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/ reimbursement structure
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/ reimbursement structure
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.8.2. Argentina
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework/ reimbursement structure
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/ reimbursement structure
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/ reimbursement structure
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/ reimbursement structure
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Company Profiles
  • 7.3.1. OMADA HEALTH, INC.
    • 7.3.1.1. Company overview
    • 7.3.1.2. Financial performance
    • 7.3.1.3. Product benchmarking
    • 7.3.1.4. Strategic initiatives
  • 7.3.2. Welldoc, Inc.
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Product benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. 2Morrow, Inc
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Product benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. Livongo Health, Inc. (Teladoc Health, Inc.)
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Propeller Health (ResMed)
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Fitbit LLC
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Mango Health
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. CANARY HEALTH
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Noom, Inc.
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Pear Therapeutics, Inc.
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Akili Interactive Labs, Inc.
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. HYGIEIA
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. DarioHealth Corp.
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Product benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. BigHealth
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Product benchmarking
    • 7.3.14.4. Strategic initiatives
  • 7.3.15. GAIA AG
    • 7.3.15.1. Company overview
    • 7.3.15.2. Financial performance
    • 7.3.15.3. Product benchmarking
    • 7.3.15.4. Strategic initiatives
  • 7.3.16. Limbix Health, Inc.
    • 7.3.16.1. Company overview
    • 7.3.16.2. Financial performance
    • 7.3.16.3. Product benchmarking
    • 7.3.16.4. Strategic initiatives